BioEcosse 2010

Characterisation of Biologics
Glasgow Science Centre
18th - 19th Jan 2010

Characterisation of Biologics 2010, Glasgow, Scotland

virus

As new products are brought to market and clinical trials, there is a requirement for those involved in the release of these products to be well informed of the regulations and technology associated with these products.

BioEcosse 2010 will allow delegates to access a wealth of information regarding these current testing requirements through various speaker’s sessions and networking opportunities. BioEcosee 2010 also includes opportunities to take part in technical sessions from market leaders in the field, allowing delegates insight into recent technological advances that allow more rapid testing and release of product.

Day 1 Agenda 18th January 2010

9:00
Registration
9:30
Introduction and Welcome to the conference - Conference Chairman Dr Daniel Galbraith, BioOutsource Ltd, UK.
9:45
Seasonal and Pandemic flu production and release
Linda Dekkers, Solvay Vaccines, The Netherlands.
10:15
New techniques in QC Release Testing
Dr. David Onions, BioReliance Inc. USA
10:50
Refreshment Break, presentation from Glasgow Science Centre
11:15
Rapid EU licensing procedures for pandemic vaccines
Jim Robertson, National Institute for Biological Standards and Control, UK
11:55
Protein Characterisation for product release using HPLC and other techniques
Shirley Bayne, Teeside University, UK.
12:30
Unwanted Immunogenicity - Critical Considerations
Andy Upsall, BioOutsource Ltd. UK
1:00
Lunch
1:45
Technical Presentations
Dr Bob Carr, Founder & Chief Technology Officer, Nanosight Technology

Human Tissue Services - Accelerating Development, Reducing Risk
Dr David Bunton, Biopta Ltd. UK

Case Studies: Analytical Technologies for Overcoming the Challenges to Biopharmaceutical Product Development
Lorna Kettle, Intertek UK
2:30
From Bench to Manufacturing. How process optimisation and scale up can affect product quality
Anita Bate, Eden Biodesign, UK
3:10
Refreshment Break
3:40
Characterisation of HSV Gene Therapy Product for Phase III Trials
Colin Love, BioVex, USA.
4:10
MycoSEQ  Mycoplasma Detection System - From Research to Biopharmaceutical Manufacturing
Stefan Meinzinger, Applied Biosystems.
5:00
End of Conference Day 1
7:00
Nexxus Sponsored Drinks Reception
7:30
Welcome speech by Rhona Allison, Director of Life Sciences at Scottish Enterprise.

Day 2 Agenda 19th January 2010

9:00
Introduction - Conference Chairman
Dr Daniel Galbraith, BioOutsource Ltd, UK
9:10
High accuracy quantification of therapeutic proteins in Pharmaceutical Cell Line Development using Gyrolab
Dr Henning von Horsten, Probiogen, Germany.
9:45
Stem cells used in the discovery of new drugs
Simon MacKenzie, Scottish Biomedical, UK.
10:15
Driving bioprocess innovation through knowledge transfer
Mark Bustard, BioProcess UK.
10:30
Break - Science show - presentation from Glasgow Science Centre
11:00
Resolving Complexity: Practical Examples of UPLC-MS for more efficient Biopharmaceutical Characterisation.
Dr St John Skilton, Waters Pharmaceuticals, UK
11:35
Is it potent? Can these results tell me? Statistics for assays.
Ann Yellowlees, Quantics Consulting Ltd, UK.
12:10
From slab gels to capillaries – Migrating Electrophoresis methods
Dr. Niall Dinwoodie, Charles River Laboratories, UK
12:40
Lunch
1:30
Developing the next generation of Host Cell Protein Assays.
Dr. Kathrin Guenther, Biogenes, Germany.
2:00
Production and QC release of EPO and GCSF products
Dr. Trevor Downey, Reliance GeneMedix, Ireland.
2:35
The Challenges of Producing and Testing GMP Grade Human Embryonic Stem Cells
Aiden Courtney, Roslin Cells, UK
3:15
Break
3:40
The best laid schemes o' mice an' men: From MMV to vCJD and the principles of risk based management for virus safety
Andy Bailey, Virusure Gmbh, Austria.
4:10
Milliprobe Mycoplasma Assay
David Lehmann, Millipore, France.
4:40
Conclusion of Conference by Chairman
Dr Daniel Galbraith, BioOutsource Ltd, UK
End of Conference